Chest
EditorialsPoint/Counterpoint EditorialsPoint: Should We Abandon FEV1/FVC <0.70 To Detect Airway Obstruction? No
References (26)
- et al.
Burden and clinical features of chronic obstructive pulmonary disease (COPD)
Lancet
(2004) - et al.
Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham Study
Am J Cardiol
(1971) - et al.
Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study
Ann Epidemiol
(1999) - et al.
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study
Lancet
(2005) - et al.
The relation between funding by the National Institutes of Health and the burden of disease
N Engl J Med
(1999) - et al.
Worldwide guidelines for chronic obstructive pulmonary disease: a comparison of diagnosis and treatment recommendations
Respirology
(2002) - et al.
Population impact of different definitions of airway obstruction
Eur Respir J
(2003) - et al.
COPD: problems in diagnosis and measurement
Eur Respir J Suppl
(2003) - et al.
Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study
Circulation
(2001) - et al.
Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study
Circulation
(1997)
Shattuck lecture. The hypertension paradox—more uncontrolled disease despite improved therapy
N Engl J Med
Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94
Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme
Eur Respir J
Cited by (54)
The 5T approach in asthma: Triple Therapy Targeting Treatable Traits
2022, Respiratory MedicineCitation Excerpt :The signal activated by ACh induces an altered structure and function, which manifests itself in an increase in the density of the parasympathetic ganglia (neuronal plasticity), resulting in an additional release of ACh and the creation of a vicious circle [28]. The classical operational definition of AL (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.70 [29]) may underestimate its presence in children and young adults and overestimate it in males aged >40 years and females >50 years [30,31]. A slightly decreased FEV1/FVC ratio in an elderly non-smoker has not the same value as in a younger smoker.
Lower limit of normal vs. fixed ratio for the diagnosis of COPD: Is it that important?
2018, Revue des Maladies RespiratoiresFamily and community medicine and chronic obstructive pulmonary disease
2015, Atencion PrimariaSociété de Pneumologie de Langue Française. Guidelines for clinical practice. Management of COPD. Update 2012: Pulmonary function tests
2014, Revue des Maladies RespiratoiresEfficacy and safety of the topical use of intranasal cinnamon bark extract in seasonal allergic rhinitis patients: A double-blind placebo-controlled pilot study
2014, Journal of Herbal MedicineCitation Excerpt :It can also be used to assess the response to therapy that is improving the air passage through bronchi, such as bronchodilators and monitoring disease progression. The FEV1% is the ratio of FEV1 to FVC (expressed as a fraction or percentage) that is the most useful spirometry parameter which is a marker of airway obstruction (Celli and Halbert, 2010; Cerveri et al., 2008; Juusela et al., 2013; Khan et al., 2010). Values of FEV1 and FVC are measured in liters and are also expressed as a percentage of the predicted values for that individual.
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Celli has been reimbursed by GlaxoSmithKline, Boehringer Ingelheim, Pfizer, AstraZeneca, Almirall, Aerys, and Esteve for participating in advisory boards and has spoken at different meetings. The division he works in has been awarded research grants for different medication trials by the same companies and for the discovery of new biomarkers in COPD. The division that Dr Celli works in has received grants for the participation in the development of biologic lung volume reduction surgery from the company AERIS. Dr Halbert serves as a consultant to the biotechnology/pharmaceutical industry, including makers of therapies for COPD.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).